EMA, FDA Talk Real World Evidence, Mutual Recognition, Generic Drugs
Executive Summary
US FDA and European Medicines Agency may expand sharing beyond manufacturing inspections to clinical trials and generic drug applications.
You may also be interested in...
When Will Real World Evidence Be Persuasive? FDA's Temple Offers Perspective
Postmarketing studies randomized to look at real world data sets could provide the key, Temple suggests; Amgen rep describes use of real world data to support approval of leukemia drug Blincyto.
EU, US Finally Agree On Mutual Recognition Of GMP Inspections
Reliance on each other’s good manufacturing practice reports should allow EU and US regulators to better focus their limited inspection resources on drug manufacturers in other countries around the world.
Novo Files Suit Over IRA As It Joins Others In Signing On To Price Negotiations
The nine drug manufacturers with products selected for Medicare drug price negotiations have agreed to participate in the program. Seven of them now have pending suits challenging the Inflation Reduction Act program with Novo’s recent complaint, which objects to the aggregation of its insulin products.